Laropiprant + Placebo for Laropiprant
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rosacea
Conditions
Rosacea
Trial Timeline
Nov 1, 2011 → Apr 1, 2012
NCT ID
NCT01451619About Laropiprant + Placebo for Laropiprant
Laropiprant + Placebo for Laropiprant is a phase 1 stage product being developed by Merck for Rosacea. The current trial status is completed. This product is registered under clinical trial identifier NCT01451619. Target conditions include Rosacea.
What happened to similar drugs?
5 of 15 similar drugs in Rosacea were approved
Approved (5) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01451619 | Phase 1 | Completed |
Competing Products
20 competing products in Rosacea